GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cannabis Global, CBGL · USD

Health Care · US listing · 🇺🇸 United States

Compare

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

—

FY2016FY2025

Net income

−$264,695

FY2016FY2025

Free cash flow

—

FY2016FY2025

Shareholders' equity

−$4.8m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue——$239,144$1.1m$1.6m$27,004————
Gross profit——$75,233−$1.4m$184,258$2,483−$752———
Research and development——————$12,450———
Operating income−$29,940−$138,000−$346,000−$2.6m−$1.9m−$3.6m−$549,918−$51,036−$43,194−$1,558
Net income−$264,695−$358,000−$1.0m−$13.8m−$7.8m−$4.9m−$389,597−$86,846−$48,094−$7,825
Diluted earnings per share-0.00-0.00-0.00-0.01-0.02-0.24-0.03-0.01-0.01-0.00

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$885,040$885,040$885,040$1.7m$11.3m$2.3m$214,829$4,652$4,832$5,012
Cash and short-term investments$11,595$11,595$11,595$85,533$30,813$2,338$152,082$4,652$4,832—
Total liabilities$6.2m$6.2m$5.9m$6.4m$10.0m$3.8m$153,414$139,605$93,893$85,643
Debt$3.8m$4.0m$3.9m$4.0m$4.0m$2.4m$47,334$92,554$70,000—
Shareholders' equity−$4.8m−$4.8m−$4.5m−$4.1m−$2.2m−$1.4m$61,415−$134,953−$89,061−$80,631
Shares outstanding6,564m4,529m1,650m924m445m20m13m12m4m6,564m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations—−$65,092−$98,224−$983,873−$1.5m−$1.5m−$109,408−$35,734−$180−$838
Capital spending—−$2−$4−$4,515−$9,511−$15,499−$14,000−$14,000−$14,000—
Free cash flow—−$65,094−$98,228−$988,388−$1.5m−$1.5m−$123,408−$49,734−$14,180−$838

Latest quarters

By quarter end

Aug 2025May 2025Feb 2025Nov 2024Aug 2024May 2024Feb 2024Nov 2023
Operating income−$6,000−$6,000−$6,000−$11,940−$6,000−$6,000−$107,020−$54,910
Net income−$61,978−$66,247−$64,936−$71,532−$65,421−$65,421−$129,870−$61,406
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Total assets$885,040$885,040$885,040$885,040$885,040$885,040$885,040$885,040
Cash and short-term investments$11,595$11,595$11,595$11,595$11,595$11,595$11,595$11,595
Debt$2.9m$3.0m$3.0m$3.1m$3.1m$3.1m$3.1m$3.1m
Shareholders' equity−$4.8m−$4.7m−$4.7m−$4.7m−$4.8m−$4.7m−$4.7m−$4.6m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-77.4%-61.7%-2.9%
Net income-73.3%-44.3%18.1%

Valuation history

At each fiscal year end

FY2025
Price to earnings-0.6

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return204700%51100%-60%-92%-96%28%100003%900%707830%2281%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 15-to-1 reverse split · 30 Sept 2019

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.